TrovaGene Inc Stock Nasdaq
Equities
US8972384080
Biotechnology & Medical Research
Sales 2024 * | 390K 531K | Sales 2025 * | 66.67K 90.73K | Capitalization | 162M 221M |
---|---|---|---|---|---|
Net income 2024 * | -45M -61.24M | Net income 2025 * | -57M -77.57M | EV / Sales 2024 * | 416 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2,435 x |
P/E ratio 2024 * |
-3.71
x | P/E ratio 2025 * |
-3.42
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.33% |
Latest transcript on TrovaGene Inc
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
1st Jan change | Capi. | |
---|---|---|
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |